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H-NMR spectrometer (EM-360, 60 MHz, Varian Instrument Division, Palo, Alto, CA, U.S.A.).
Chemicals and Materials
The following authentic standards were used after confirming their purity and compliance with the pharmaceutical requirements. Amifloxacin (Sterling Winthrop Inc., U.S.A.), ciprofloxacin HCl (Miles Inc. Pharmaceutical Division, West Haven, Germany), difloxacin HCl (Abbott Laboratories, North Chicago, U.S.A.), enrofloxacin (Merck, Darmstadt, Germany), gatifloxacin (Bristol-Myers Squibb S.A.E., Cairo, Egypt), levofloxacin (Aventis Pharma S.A.E, Cairo, Egypt), lomefloxacin HCl (Searle, Illinois, U.S.A.), norfloxacin HCl (Egyptian International Pharmaceutical Industries Co., Cairo, Egypt), ofloxacin (Daiichi, Tokyo, Japan), pefloxacin methanesulphonate (Rhone-Poulenc Rorer, Neuilly/Seine, France), and sparfloxacin (Global Napi Pharmaceuticals, Cairo, Egypt). N-Bromosuccinimide (NBS; Aldrich Co., Ltd., Gillingham-Dorst, Germany) was 0.5 mg/ml aqueous solution. Hydrochloric acid was obtained from El-Nasr Pharmaceutical Chemicals Co. (Cairo, Egypt). p-Phenylenediamine (PDA; Loba Chemie PVT. Ltd., Mumbai, India) was used at a concentration of 0.1 mg/ml in 0.01 M HCl solution. DC Alufolien, Kiesselgel 60 F254 precoated TLC plates were purchased from E. Merck (Darmastadt, Germany). All other chemicals and solvents used throughout this study were of analytical grade.
Pharmaceutical Dosage Forms The following pharmaceutical formulations were obtained from the local markets and analyzed. Ciprofloxacin ® tablets (Amriya Pharmaceutical Industries, Alexandria, Egypt) are labeled to contain 500 mg of ciprofloxacin HCl per tablet. Ciprofloxacin ® intravenous infusion (Amriya Pharmaceutical Industries, Alexandria, Egypt) is labeled to contain 200 mg of ciprofloxacin lactate per 100 ml infusion. Cipro ® optic drops (Chemical Industries Development Co., Giza, Egypt) are labeled to contain 3. Preparation of Standard and Sample Solutions Preparation of Stock Standard Solution: Into a 50-ml calibrated flask, 100 mg of the drug was accurately weighed and dissolved in about 40 ml of 0.01 N HCl. For complete dissolution of norfloxacin, lomefloxacin, enrofloxacin, amifloxacin, gatifloxacin, and sparfloxacin, the contents of the flask was sonicated for 5 min. The resulting solutions were completed to volume with 0.01 N HCl. These stock solutions (2 mg/ml) were diluted with 0.01 N HCl to obtain the suitable concentrations that lie in the linear range of the assay method for each particular drug.
Preparation of Tablets Sample Solutions: Twenty tablets were weighed and finely powdered. A quantity of the powdered tablets equivalent to the content of one tablet was transferred into a 100-ml calibrated flask, dissolved in 80 ml 0.01 N hydrochloric acid, swirled and sonicated for 10 min. The contents were diluted to volume with the corresponding solvent (as in stock solutions), shaken well for 15 min, and filtered. The first portion of the filtrate was rejected, and a measured volume of the filtrate was diluted quantitatively with 0.01 N HCl to yield suitable concentrations that were in the linear range of each particular drug.
General Analytical Procedure One milliliter of the standard or sample solution was transferred into a 10-ml calibrated flask. One milliliter of NBS reagent solution (0.5 mg/ml) was added and mixed. The reaction was allowed to proceed for 15 min at room temperature (25Ϯ5°C). One milliliter of PDA reagent solution (0.1 mg/ml) was added and mixed. The reaction was allowed to proceed for 5 min at room temperature (25Ϯ5°C). The volume was then completed to the mark with distilled water. The decrease in the absorbance (DA) of the solution was measured at 530 nm against reagent blanks treated in a similar manner. The positions of the cuvettes of the samples and the blanks were exchanged for direct measurement of the decrease in the absorbance.
Determination of Molar Ratios of the Reactions Reaction of NBS with FQA: The Job method of continuous variation was used. 23) Master equimolar solutions (1ϫ10 Ϫ3 M) of the investigated drugs and NBS reagent were prepared. Series of 10-ml portions of the master solutions of drugs and reagent were prepared comprising different complementary proportions (0 : 10, 1 : 9, … , 9 : 1, 10 : 0, inclusive) in 25-ml calibrated flasks. The reactions were allowed to proceed for 15 min at room temperature (25Ϯ5°C), and then 1 ml of PDA reagent (0.1 mg/ml) was added. The flasks were allowed to stand for 5 min, and then completed to the mark with water. The decrease in the absorbance (DA) values of the resulting solutions was measured at 530 nm.
Reaction of NBS with PDA: One-milliliter aliquots of NBS solution (5.4ϫ10 Ϫ3 M) were transferred into 25-ml calibrated flasks. To each flask, 1 to 10 ml aliquots of PDA solution (5.4ϫ10 Ϫ3 M) were added, and the reactions were allowed to proceed for 5 min at room temperature (25Ϯ5°C). The reaction mixtures were completed to volume with water, and the absorbance was measured at 530 nm against reagent blanks prepared without NBS. mixed. The reaction was monitored by TLC until it gave a single spot different from that of the norfloxacin spot; the reaction proceeded for 30 min. The formed yellowish white precipitate that formed was filtered, washed 3 times with diethyl ether and then dried over anhydrous sodium sulphate. The dried material (mp 275°C) was analyzed by UV-vis., IR, and 1 H-NMR spectrometry for its structure elucidation.
Preparation of the Reaction Product between NBS and Norfloxacin

Results and Discussion
Reactions Involved and Absorption Spectra The analytical reaction involved two steps; the first one was concerned with the treatment of the investigated FQA with a known excess amount of NBS. The second step involved the determination of the excess unreacted NBS via its reaction with PDA reagent. The reaction of the investigated FQA with NBS was monitored by measuring the excess unreacted NBS at different time intervals via formation of a chromogenic product with PDA. The addition of PDA solution to the NBS solution resulted in the formation of a violet colored product that showed l max at 530 nm, whereas the FQA, NBS, and PDA had no absorption capability above 360 nm (Fig. 1) . The decrease in the absorption intensity (DA) at 530 nm, caused by the presence of the FQA, was directly proportional to the amount of the drug in its original sample.
Optimization of Reaction Variables Concentration of NBS and PDA: According to the above-mentioned reaction, NBS solution should be added in excess to react with the FQA. By measuring the excess NBS reagent, the consumed reagent would correspond to the amount of the drug. The highest concentration of NBS reagent that reacts with a definite concentration of PDA reagent (in absence of FQA) and gives the highest absorption value within the practical sensitivity range of absorption values (ca. 0.9) was considered as optimum. The effect of NBS reagent concentration was studied by carrying out the reaction using 1 ml of different concentrations in the range of 0.05-1 mg/ml. In this study, 1 ml of PDA reagent (0.1 mg/ml) was used for color development. The results revealed that the DA values increased by increasing the concentration of NBS until the maximum DA value was obtained at a concentration of 0.4-0.5 mg/ml, and further increase in the concentration of the reagent had a slight negative effect on the DA values (Fig. 2) . A concentration of 0.5 mg/ml was selected for the subsequent experiments. Using this concentration, similar series of experiments were performed to establish the optimum concentration of PDA reagent. The results revealed that the optimum concentration of PDA was 0.1 mg/ml (Fig. 2) .
Reaction Time and Temperature: Under these conditions, the reaction between the investigated drugs and NBS was completed within 10 min at room temperature (25Ϯ5°C), and the DA values remained unaffected up to 20 min, however, a longer reaction time had a negative effect (Fig. 3) . For more precise readings the reaction was allowed to proceed for 15 min. Although Fig. 3 illustrates the effect of time on the reaction of NBS with lomefloxacin, norfloxacin, and sparfloxacin, as representative examples, however similar results were obtained with the other investigated FQA. After addition of PDA reagent, complete color development was achieved within 5 min. Elevated temperatures had no significant accelerating effect on the reaction.
Diluting Solvent and Stability of the Chromogen: Dilution of the reaction mixture with different solvents showed that the position of l max and the absorption intensities were affected. The highest readings were obtained when water was used as a diluting solvent. Substitution of water with other solvents (ethanol, acetone, propan-1-ol, propan-2-ol, butan-1-ol, and 1,4-dioxane) resulted in slight bathochromic shifts, and the absorption intensities were depressed. The absorbance values (A) were correlated with the dielectric constants (DEC) of the solvents used for dilution. 24, 25) The correlation equation was: Aϭ0.7836ϩ0.0029DEC (r 2 ϭ0.8241). After dilution with water, the absorbance values were found to be stable for at least 30 min.
Molar Ratio and Reaction Mechanisms Reaction of FQA with NBS: Examination of the stoichiometry for the The concentrations of the drugs were 5, 10, and 12 mg/ml for norfloxacin, levofloxacin, and sparfloxacin, respectively. reaction between FQA and NBS revealed that FQA : NBS ratio was 1 : 1 (1 mol of FQA reacts with 1 mol of NBS) in the cases of gatifloxacin, levofloxacin, lomefloxacin and sparfloxacin, and the ratio was 1 : 2 (1 mol of FQA reacts with 2 mol of NBS) in the cases of amifloxacin, ciprofloxacin, difloxacin, enrofloxacin, norfloxacin, and pefloxacin.
In order to propose a possible reaction pathway, the product of the reaction between NBS and norfloxacin, as a representative example for FQA, was isolated and examined by different techniques. The product was a yellowish material with a mp of 275°C. The product had a maximum UV absorption peak (l max ) at 383 nm; norfloxacin itself showed l max at 325 nm. The absorption spectrum of the isolated product was the same as that of the reaction mixture between NBS and norfloxacin. The IR spectrum (obtained in KBr disc) of the product showed the disappearance of the carboxylic acid CϭO stretch of norfloxacin at 1725-1700 cm
Ϫ1
, and also the carboxylic hydroxyl group at 3600-3250 cm
. However, the IR spectra of both norfloxacin and its reaction product with NBS showed the pyridone CϭO stretch at 1628 cm
. These data indicated the decarboxylation of norfloxacin. This assumption was supported by the failure of the isolated reaction product to give a positive comlexation reaction with FeCl 3 solution, rather than norfloxacin, which gave a red colored complex. 26) The 1 H-NMR spectrum (DMSO-d 6 ) of the product showed the absence of a doublet signal that should appear if a proton at C 3 is present, and also the disappearance of the carboxylic group proton that appears offset (Fig. 4) . Based on this observation, decarboxylation with substitution for the C 3 proton with bromine was suggested. This suggestion was also evidenced by the appearance C 2 of the proton as a singlet, rather than a doublet peak if a proton at C 3 is available for coupling. Bromination at C 8 was also suggested by the disappearance of the doublet signal of C 8 proton (at 7.2 ppm in NMR spectrum of norfloxacin. These data, in conjunction with the norfloxacin : NBS molar ratio (2 : 1) confirmed the bromination at both C 2 and C 8 . The proposed pathway for the reaction between norfloxacin and NBS is given in Fig. 5A . These results were coincident with the reported ability of NBS to accomplish substitution of the bromine for the hydrogen in reactive aromatic compounds in positions a to double bonds and aromatic rings, and also in positions a to the carbonyl groups. 27) Reaction of NBS with PDA: The molar ratio of the reaction between NBS and PDA, that gives the colored product, was found to be 1 : 2. This indicated that 1 mol of NBS reacted with 2 mol of PDA. Based on this finding, the reaction was postulated to proceed according to the pathway given in Fig. 5B . One molecule of PDA was oxidized with NBS to give p-benzoquinonediimine, which was further oxidized to produce p-benzoquinone.
28) The produced p-benzoquinone was further condensed with a second molecule of PDA to give the conjugated violet product.
Development and Validation of the Analytical Method Linearity, Limits of Detection and Quantitation: Under the above-mentioned optimum conditions, the calibration graphs correlating the decrease in the absorption intensity (DA) with the corresponding concentration of the drug were constructed. Regression analysis for the results was as carried out using the least-square method. In all cases, Beer's law plots (nϭ5) were linear with very small intercepts (Ϫ0.020-0.0302) and good correlation coefficients (0.9982-0.9998) in the general concentration ranges of 3-25 mg/ml ( Table 2 ). The limits of detection (LOD) and limits of quantitation (LOQ) were determined 29) using the formula: LOD or LOQϭkSD a /b, where kϭ3 for LOD and 10 for LOQ, SD a is the standard deviation of the intercept, and b is the slope. The LOD and LOQ values ranged from 0.33-1.29 and 1.12-4.31 mg/ml, respectively.
Investigations were carried out to correlate the chemical structure with the analytical parameters. The obtained log e values were correlated, using regression analysis, with some physicochemical parameters of the investigated compounds: pK a , clogP, Van der Waal forces (VDW), heat of formation It was observed that the sensitivity of the method, in terms of log e value, was positively correlated with the Van der Waal forces and pHF, while good negative correlations were found with the pK a values and HF.
Precision: The precision of the proposed method was determined by analyzing 6 replicate samples of standard FQA solutions at one concentration level for each drug. The assays gave satisfactory results; the relative standard deviations (RSD) were less than 2%. This level of precision of the proposed methods was adequate for the quality control analysis of the investigated FQA in the pharmaceutical dosage forms.
Interference Liabilities: Before proceeding with the analysis of the investigated drugs in their pharmaceutical dosage forms, interference liabilities were carried out to explore the effect of common excipients that might be added during formulations. Samples were prepared by mixing known amount (30 mg) of the drug with various amounts of the common excipients: lactose, sucrose, starch, magnesium stearate, and ascorbic acid sodium salt (co-formulated with pefloxacin as stabilizer in the ampoule form). The analysis of these laboratory-prepared samples were carried out using the general recommended procedure, and the recovery values were determined. No interference was found from lactose, sucrose, starch, and magnesium stearate; the recovery values were 98.8-100.8Ϯ0.24-1.43%. This indicated the absence of interference from these excipients. On the other hand, ascorbic acid was found to interfere with the assay procedure (the recovery value was 105.9Ϯ0.85%). This interference was attributed to the liability of ascorbic acid to the oxidation with NBS. 30) This interference could be eliminated by adding 1 ml of 0.1% (w/v) aqueous solution of potassium bromate to the pefloxacin-containing ampoule samples prior to their analysis; the recovery was reduced to 101.3Ϯ0.74%. The selection of potassium bromate for this purpose was based on its mild oxidizing power (E 0 BrO 3 /Br ϭϩ0.76 V) that can oxidize ascorbic acid without affecting the drug. Tinidazole which was co-formulated with norfloxacin in CONAZ ® tablets did not show any interference. In addition, the proposed method has the advantage that the analysis is performed at 530 nm of the visible region away from the UV-absorbing capabilities of interferents that might be co-extracted from dosage forms.
Robustness and Ruggedness: Robustness was examined by evaluating the influence of small variation of method variables (concentration of the analytical reagents, and reaction time) on the performance of the proposed method. In these experiments, one parameter was changed where as the others were kept unchanged, and the recovery percentage was calculated each time. It was found that none of these variables significantly affect the method; the recovery values were 98.1-100.6Ϯ0.19-0.98%. This provided an indication for the reliability of the proposed method during its routine application for analysis of the investigated drugs.
Ruggedness was tested by applying the proposed method to the assay of the same samples of the investigated drugs using the same operational conditions but using two different instruments at two different laboratories and at different elapsed times. Results obtained from instrument-to-instrument and day-to-day variations were found to be reproducible, as the RSD did not exceed 2%.
Application of the Proposed Method to Analysis of Dosage Forms It is evident from the aforementioned results that the proposed method gave satisfactory results with the investigated drugs in bulk. Thus their pharmaceutical dosage forms were subjected to the analysis for their contents of the active ingredient by the proposed method and the official method. The label claim, as percentages, ranged from 99.4-100.5Ϯ0.16-0.63% (Table 3) . These results were compared with those obtained from the official 31) or the reported 32, 33) methods by statistical analysis with respect to the accuracy (t-test) and precision (F-test). No significant differences were found between the calculated and theoretical values of t-and F-tests at the 95% confidence level proving similar accuracy and precision in the analysis of the investigated drugs in their dosage forms.
Conclusions
The results demonstrated the usefulness of the NBS-PDA system in the spectrophotometric analysis of fluoroquinolone antibiotics. The proposed method is characterized by its high sensitivity, which permits the determination of a concentration down to 0.33 mg/ml, procedural simplicity of the procedures, and reliability of the results. Furthermore, the analytical reagents are inexpensive, have excellent shelf life, and are available in any analytical laboratory. The proposed method can be applied in quality control laboratories for the routine analysis of the investigated drugs in raw materials, in pharmaceutical formulations.
